Midostaurin

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Systemic Mastocytosis, Aggressive (ASM)

Conditions

Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD)

Trial Timeline

Mar 1, 2005 → Apr 16, 2011

NCT ID

NCT00233454

About Midostaurin

Midostaurin is a phase 2 stage product being developed by Novartis for Systemic Mastocytosis, Aggressive (ASM). The current trial status is completed. This product is registered under clinical trial identifier NCT00233454. Target conditions include Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD).

What happened to similar drugs?

10 of 20 similar drugs in Systemic Mastocytosis, Aggressive (ASM) were approved

Approved (10) Terminated (4) Active (7)

✅Baricitinib + CyclophosphamideEli LillyApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03114228	Pre-clinical	Completed	—	—	FLT3-mutated Acute Myeloid Leukemia
NCT05219266	Pre-clinical	Completed	—	—	FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia
NCT02624570	Pre-clinical	Completed	—	—	Acute Myeloid Leukemia (AML) With
NCT05488613	Pre-clinical	Completed	Sep 24, 2020	Jan 26, 2021	Acute Myeloid Leukemia (AML)
NCT01883362	Phase 2	Completed	Feb 6, 2014	Apr 30, 2018	Acute Myeloid Leukemia
NCT00866281	Phase 1/2	Terminated	Sep 1, 2009	Sep 1, 2014	Acute Myeloid Leukemia
NCT00233454	Phase 2	Completed	Mar 1, 2005	Apr 16, 2011	Systemic Mastocytosis, Aggressive (ASM)

Competing Products

20 competing products in Systemic Mastocytosis, Aggressive (ASM)

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Cyclophosphamide	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29